Abstract
Guselkumab is the first IL-23 inhibitor registered for the treatment of psoriatic arthritis (PsA), lnterleukin-23 plays a key role in both psoriasis and psoriatic arthritis. Guselkumab is already approved for the treatment of plaque localized psoriasis and several clinical trials háve demonstrated its efficacy in active PsA - in different forms °f the disease and in different types of patients (after failure of standard treatment, after failure of TNF-a inhibitor treatment as well as in patients not yet biologically treated).
Its efficafcy on arthritis is at least comparable to °ther biologics (however, a direct comparative study is still lacking), its effect on the cutaneous manifestations of Psoriasis is robust and probably higher than that of other biologics. Treatment may be accompanied by side effects such as upper respirátory tract infections, post-injection reactions, generál allergic reactions, etc.
Opportunistic infections and tuberculosis háve not been observed during the treatment with guselkumab. Guselkumab is administered subcutaneously at a dose of 100 mg at weeks 0, 4 and every 8 weeks thereafter